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Abstract 
Background: the usefulness of performing a spinal cord (SC) MRI in all 
clinically isolated syndromes (CIS) is controversial. 
Objective: to assess the value of SC lesions for predicting MS diagnosis and 
disability accrual in CIS.  
Methods: concerning SC lesions and MS diagnosis (2010 McDonald), adjusted 
Cox regression analyses were performed in increasingly specific CIS groups: all 
cases (n=207), non-SC CIS (n=143), non-SC CIS with abnormal brain MRI 
(n=90), and non-SC CIS with abnormal brain MRI not fulfilling 2010 MS (n=67). 
For the outcome EDSS ≥3.0, similar analyses were performed in all cases 
(n=207), non-SC CIS (n=143), and SC CIS (n=64). Performance at two years 
was assessed for all outcomes.  
Results: presence of SC lesions increased MS risk 2.0-2.6 times independently 
of factors like brain lesions. If considering lesion number, the risk ranged from 
1.6-2.1 for one lesion to 2.4-3.3 for ≥2. SC lesions increased the short-term 
disability risk around fivefold, better demonstrated in non-SC CIS. SC lesions 
were very specific for evolution to MS and showed very high sensitivity for 
EDSS ≥3.0.   
Conclusions: SC lesions are independent predictors of MS in all CIS and 
contribute to short-term disability accrual. SC MRIs in CIS could be useful to 
estimate their prognosis. 
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Introduction 
Technical improvements have mitigated the challenges of spinal cord (SC) 
MRI,1 leading to its routine acquisition in the diagnostic work-up of patients with 
clinically isolated syndromes (CIS) in some institutions. Besides, SC lesions 
can provide evidence of dissemination in space (DIS) in the 2010 McDonald 
criteria.2 Nevertheless, some studies conclude that SC MRIs should be 
performed only when the presenting symptoms suggest a myelitis or when brain 
MRI findings are inconclusive for MS.3-7 Furthermore, there is limited 
information regarding the predictive value of SC lesions on evolution to MS 8, 9, 
their added value at baseline for diagnosing MS,8, 10, 11 and their role in disability 
accrual,12, 13 particularly in non-SC CIS. Consequently, the usefulness of 
systematically performing a SC MRI at the time of a CIS is still considered 
controversial, especially in presentations other than myelitis.14-16  
Therefore, our objective was to evaluate the added value of SC lesions in CIS 
for reaching a diagnosis of MS and predicting disability accrual.  
 
Materials and Methods  
Study cohort  
This study was based on a longitudinal, open CIS cohort at the MS Centre, Vall 
d’Hebron University Hospital, Barcelona. Patients <50 years of age first seen 
within three months of disease onset were included.17 Demographic data, CIS 
topography, and disability according to the Expanded Disability Status Scale 
(EDSS) were recorded at baseline. IgG oligoclonal bands (OCB) were 
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determined within the first three months. Follow-up was performed every 3-6 
months assessing for relapses and the EDSS measured during stability periods.  
Concerning MRI acquisition and analysis, baseline brain MRIs were performed 
within 3-5 months of disease onset and follow-up scans at one year and every 
five years. Before 2007, SC MRIs were done if the presenting symptoms 
suggested a myelitis and in all CIS thereafter. Scans were obtained at 3.0 Tesla 
(T) since 2010 and at 1.5 T previously. Brain sequences included dual echo T2-
weighted fast spin-echo, transverse and sagittal T2-weighted FLAIR, and 
transverse T1-weighted spin-echo. The transverse T1-weighted sequence was 
repeated after gadolinium (Gd) injection (gadobutrol, 0.2 mmol/kg) in patients with 
lesions on T2-weighted images (T2WI). SC sequences included sagittal dual 
echo proton density/T2-weighted fast spin-echo, sagittal short-tau inversion-
recovery (STIR) and, in patients with brain Gd T1-weighted sequences or SC 
lesions, a Gd-enhanced sagittal T1-weighted. Axial T2-weighted sequences 
covered segments showing abnormalities on the sagittal images or with 
suspected clinical involvement. 
All sequences were acquired with a contiguous 3-mm section thickness. Each 
MRI scan, performed in the daily practice, was assessed by one of two 
experienced neuroradiologists blinded to clinical follow-up. In doubtful cases, 
the final analysis was based on their consensus opinion.  
MRIs were considered abnormal if ≥1 lesion was observed. The number and 
location of lesions on T2WI, number of Gd-enhancing and new T2 lesions on 
brain MRI, as well as lesion number (0, 1, 2-3, >3) and presence of Gd 
enhancement on SC were scored.  




From this cohort, 100 consecutive patients with baseline brain and SC MRI at 
3.0 T and 107 at 1.5 T were identified between 2007 and 2012. Baseline 
demographic and clinical characteristics were compared (data not shown). 
There were no significant differences except for CIS topography due to a higher 
number of optic neuritis in the 3.0 T group [3.0 T: 43 (43.0%) vs. 1.5 T: 27 
(25.2%), p=0.038]. Furthermore, in accordance to a previous study,18 there 
were no significant differences in SC lesion detection between MRI scans at 3.0 
and 1.5 T in the entire CIS cohort [39/100 (39.0%) vs. 54/107 (50.5%), 
p=0.124], in SC CIS [17/24 (70.8%) vs. 33/40 (82.5%), p=0.353], and in non-SC 
CIS [22/76 (28.9%) vs. 21/67 (31.3%), p=0.855]. Therefore, both groups were 
merged (n=207) for the analyses, keeping field strength as a covariate in 
survival models.  
 
Statistical Analysis 
Henceforth, the term “MS” may refer to either CDMS (clinical) or McDonald MS 
(clinical or radiological).  
Descriptive statistics were performed on demographic and clinical variables. 
 
Added value of SC lesions for MS diagnosis 
To evaluate whether baseline SC assessment could be more useful in specific 
clinical practice scenarios, Kaplan-Meier Meyer curves and uni- and 
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multivariable Cox proportional hazards regression analyses were performed in 
the following increasingly specific groups according to presence vs. absence of 
SC lesions with 2010 McDonald MS 2 and CDMS 19 as the outcomes during the 
total follow-up time:   
- All cases considering symptomatic and asymptomatic SC lesions  
- Non-SC CIS regardless of brain MRI findings 
- Non-SC CIS with abnormal brain MRIs irrespective of DIS and DIT 
fulfilment 
- Non-SC CIS with abnormal brain MRI not fulfilling DIS and DIT 
Multivariable survival analyses were adjusted by age, sex, CIS topography, 
OCB, T2 brain lesion number (0, 1-3, 4-9, ≥10), magnet field strength, and 
disease modifying treatment (DMT) (before CDMS, McDonald MS) as a time-
dependent variable. A “missing” category was added for patients with no OCB 
determination. Results for multivariable analyses are expressed as adjusted 
hazard ratios (aHR).  
A similar survival analysis was performed according to SC lesion number (0, 1, 
≥2) for the two MS outcomes.  
As a secondary objective, we studied the added value of SC MRI in the 
fulfilment of the 2010 McDonald criteria at baseline. Given SC MRIs are almost 
invariably performed in myelitis cases, we focused on the 143 (69.1%) non-SC 
CIS using the following approach: we determined the proportion of patients 
fulfilling an alternative criterion assessing the presence of ≥2/3 DIS criteria on 
baseline brain MRI, and then used both brain and SC MRI to evaluate the 
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presence of ≥2/4 DIS criteria, to finally determine how many patients fulfilled 
radiological DIS and DIT in each scenario. Afterwards, the number needed to 
scan (NNS) to diagnose one additional case was calculated.8  
 
Added value of SC lesions for predicting disability accrual  
Using EDSS ≥3.0 assessed from month 12 of follow-up as the disability 
outcome according to presence of SC lesions, Kaplan-Meier Meyer curves and 
uni- and multivariable Cox proportional hazards regression analyses were 
performed in:   
- All cases (n=207)  
- SC  CIS (n=64) 
- Non-SC CIS (n=143) 
The multivariable survival analyses were adjusted by the previously mentioned 
covariates, considering DMT before EDSS ≥3.0.  
 
In all Cox regression models, we evaluated the proportionality of hazards 
assumption using the Grambsch-Therneau test. 
 
SC lesions’ performance 
We assessed the performance of baseline SC lesions (dichotomic variable) with 
the outcomes CDMS, 2010 McDonald MS, and EDSS ≥3.0 at two years in the 
previously mentioned groups. Sensitivity, specificity, accuracy, positive 
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predictive value (PPV), and negative predictive value (NPV), all with exact 
binomial 95% CI, were calculated. 
 
Statistical tests were performed on the 0.05 level of significance using IBM 
SPSS Statistics (SPSS Inc., Chicago, IL, USA), version 20.0. 
 
This study received approval from the Clinical Research Ethics Committee at 





Of all 207 patients, two thirds were female with a mean (SD) age of 32.6 (8.1) 
years. A SC CIS occurred in 30.9%. Regarding brain MRI, 65.2% had ≥1 lesion. 
The SC MRI demonstrated ≥1 lesion in 44.9% (78.1% SC vs. 30.1% non-SC 
CIS, p<0.0001) (Table 1). Figure 1 shows a representative non-SC CIS case 
with SC lesions. 
 
Please insert Table 1 and Figure 1 here. 
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These baseline characteristics were comparable with the rest of the CIS cohort 
not selected for this study (n=807, data not shown), except for age [30.7 (8.2), 
p=0.004].     
Outcome measures 
During a mean follow-up of 35.7 (15.8) months, 29.5% of patients developed 
CDMS, 44.9% fulfilled the 2010 McDonald criteria, and 6.3% reached an EDSS 
≥3.0. The median (percentiles 25-75 IQR) time to CDMS was 8.7 (4.3-24.0) 
months, 4.7 (3.3-12.0) for McDonald MS, and 24.0 (12.0-36.0) for EDSS ≥3.0.   
 
Results according to CIS topography (SC and non-SC) are shown in Table 1. 
The corresponding data for the other two CIS groups are shown in Annex 1.       
 
Added value of SC lesions for MS diagnosis 
When evaluating McDonald MS, Kaplan-Meier curves showed that patients with 
SC lesions had a higher risk of fulfilling this outcome in all groups (Figure 2). 
Moreover, when controlling for other variables, all the aHRs were significantly 
increased, between 2.0 and 2.6 times (Table 2).  
 
Please insert Figure 2 and Table 2 here. 
 
If considering SC lesion number, the aHRs ranged from around two-fold for one 
SC lesion to 2.4-3.3 for ≥2 lesions (Table 3).   
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Please insert Table 3 here. 
 
Regarding CDMS, more patients with SC lesions reached this outcome than 
those with no lesions (Figure 3). Presence of SC lesions posed an increased 
risk for CDMS in all 207 patients (aHR 1.9, 95% CI 1.03-3.6, p=0.041), losing 
significance as CIS groups became smaller (aHR 1.9, 95% CI 0.9-4.0, p=0.080 
for all non-SC CIS). The HRs also increased along with lesion number, losing 
significance in the multivariable analyses (data not shown). 
 
Please insert Figure 3 here. 
 
As for the added value of SC MRI in the fulfilment of the 2010 McDonald criteria 
at baseline, the NNS decreased from 36 in all non-SC CIS to 17 in cases with 
abnormal brain scans not fulfilling DIS and DIT (Table 4).  
 
Please insert Table 4 here. 
 
Added value of SC lesions for predicting disability accrual  
The presence of SC lesions was associated with a greater risk of reaching an 
EDSS ≥3.0, observed in 11/93 (11.8%) cases vs. 2/114 (1.8%) in the group 
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without SC lesions (p=0.003). We found no differences in the proportion of 
patients reaching an EDSS ≥3.0 according to CIS topography [6/64 (9.4%) SC 
vs. 7/143 (4.9%) non-SC, p=0.352]. The presence of SC lesions increased the 
risk of reaching an EDSS ≥3.0 when evaluating all 207 patients and was 
especially significant in non-SC CIS (Figure 4 and Table 5). In the SC CIS 
model we only introduced sex, age, and SC lesions as no cases were observed 
in the other covariates.  
 
Please insert Figure 4 and Table 5 here. 
 
We observed no deviation from proportionality after fitting all Cox models using 
the Grambsch-Therneau test (p from 0.3061 to 0.6648). 
 
SC lesions’ performance 
Concerning McDonald MS at two years, presence of SC lesions showed a very 
good specificity and PPV, especially in non-SC CIS (Table 2). 
Performance of SC lesions for CDMS showed a good specificity, especially in 
non-SC CIS groups (from 63.4% to 76.5%), with a good NPV in all groups (from 
65.7% to 76.9%). 
Finally, the presence of SC lesions was highly sensitive and had a very good 
NPV for EDSS ≥3.0 (Table 5). 
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Discussion 
This study shows that the presence of SC lesions is an independent risk factor 
for reaching a diagnosis of MS regardless of other demographic or clinical-
radiological factors. This effect was better demonstrated for McDonald MS 
possibly due to the higher number of patients reaching this outcome 2 compared 
to CDMS. Importantly, our analyses show that MS risk increases with a higher 
SC lesion number, better demonstrated in McDonald MS.  
Other studies have evaluated the diagnostic role of SC lesions in CIS. Patrucco 
and colleagues studied 75 patients with typical CIS topographies and found a 
≥3.5-fold risk for CDMS independently of brain lesions, OCB, and CIS 
topography.9 Sombekke and colleagues assessed four CIS groups and found 
that presence of SC lesions conferred the highest CDMS risk in non-SC cases 
not fulfilling the MS criteria on brain MRI.8 One important advantage in our study 
is the possibility to assess baseline demographic, clinical, CSF, and brain 
imaging data in differing multivariable models. Our results indicate that both 
presence and increasing number of SC lesions pose a two- to threefold risk for 
evolving to MS regardless of the initial brain MRI findings. These findings also 
suggest that not only lesion number, but also lesion location irrespective of the 
initial clinical presentation, may play a role in defining MS risk, as previously 
demonstrated with infratentorial lesions.20, 21  
When evaluating the role of SC MRI on fulfilling the 2010 McDonald criteria at 
baseline, our results, compared to previous publications, suggest that criteria 
fulfilment may differ according to the studied population’s baseline findings. For 
instance, Sombekke and colleagues observed that only seven scans were 
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needed to diagnose one additional patient in a CIS cohort comprising 121 
individuals with highly pathological baseline MRIs.8 Conversely, Dalton and 
colleagues assessed 115 patients with optic neuritis, 27.0% of them with SC 
lesions, and found that SC MRI allowed the diagnosis in one additional patient 
at one year and in two at three years after applying the 2001 criteria.10, 22 
Finally, a study of 41 paediatric CIS showed the McDonald criteria were fulfilled 
through DIT in four additional patients when including the SC scan in the 
analysis.11 In our cohort, the NNS improved by eliminating cases with normal 
brain MRIs and especially when assessing SC scans in patients with abnormal 
brain MRIs not fulfilling the diagnostic criteria. Nevertheless, if the criteria are 
not fulfilled at baseline even after adding the SC MRI findings, these patients 
still merit a close clinical-radiological monitoring if they presented a typical CIS 
and/or have suggestive lesions.23  
As for the prognostic value of SC lesions in disability accrual, Swanton and 
colleagues evaluated 100 optic neuritis cases and observed that presence of 
SC lesions was a predictor for reaching a higher disability outcome (ranked 
EDSS: 0, 1, 1.5-2.0, ≥2.5) together with Gd-enhancing and new T2 lesions (OR 
3.30, 95% CI 1.26-8.68). When evaluating SC lesion number (0, 1, 2, ≥3), SC 
lesions were predictors of disability together with infratentorial and new T2 
lesions. And in patients who developed CDMS, the only predictor was presence 
or number of SC lesions.12  
Brownlee and colleagues assessed 131 non-SC CIS with a median follow-up of 
5.2 years, observing that SC measures such as baseline lesion number, change 
in lesion number and change in upper cervical cord cross-sectional area were 
independently associated with reaching an EDSS ≥3.0 (R2=0.53), whereas 
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adding brain MRI data only modestly increased the model´s predictive value 
(R2=0.64).13  
In our study, we found that presence of SC lesions increases the risk of short-
term disability accrual around fivefold, better demonstrated in non-SC CIS. That 
does not mean SC CIS patients have a lower risk of reaching this outcome. It 
could be argued that radiological demonstration of SC lesions in non-SC CIS 
may improve discriminating patients at higher risk of developing disability by 
providing additional information already demonstrated clinically in SC CIS. That 
the latter comprises the smallest group with only one patient without SC lesions 
affecting the survival analyses also may have played a role in our results. 
Therefore, our study is limited by the few patients reaching the disability 
outcome during our short follow-up. The significant results Swanton and 
colleagues found might be related not only to their longer follow-up, but also to 
their definition of disability, as ours is more restrictive. However, we also 
consider it a more robust outcome since inter-observer variability is high with 
lower EDSS scores and, from the clinical point of view, an EDSS of 3.0 
represents moderate disability. One advantage of our study is the better 
representation of non-SC CIS topographies other than optic neuritis compared 
to the two aforementioned studies, with the latter having an overrepresentation 
of this topography (87%).13  Unfortunately, we did not test SC lesion number 
due to the few patients reaching our outcome. Moreover, we did not assess the 
precise location of SC lesions in the transverse plane and, consequently, could 
not establish the relevance of gray matter involvement. Other sequences, such 
as high resolution phase sensitive inversion recovery, which can delineate the 
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gray/white matter boundaries on the axial plane, were not obtained due to the 
long acquisition time even with 3.0 T magnets.24, 25 
Regarding SC lesion performance, our results confirm the high specificity they 
confer to MS diagnosis,2, 22, 26-29 mostly in non-SC CIS and with McDonald MS 
as the outcome. This underscores their important role in the differential 
diagnosis of MS. Besides, their high PPV supports their usefulness for 
McDonald MS diagnosis in the clinical practice. Taking these results together 
with the regression analyses findings, our data indicates that both presence and 
number of SC lesions may further contribute to individualize MS risk.17   
When considering performance at two years with EDSS ≥3.0 as the outcome, 
SC lesions were highly sensitive for disability accrual, while the high NPV, 
particularly in non-SC CIS, suggests the probability of reaching an EDSS ≥3.0 
in the short-term is very low if no SC lesions are present. Therefore, the 
presented results support the notion that SC lesions might pose a higher risk for 
short-term disability. This implies that lesion topography could also be assessed 
to consider the use of highly effective DMTs, but specific studies on this subject 
are needed.30   
Nonetheless, an important limitation of our work is the limited follow-up, 
hindering our disability analysis. Further studies, including a future 
reassessment of the present cohort, are required to confirm the prognostic role 
of baseline SC lesions in the medium- to long-term.  
Other limitations include the small number of patients in several subgroups and 
the impossibility to assess the SC lesion number as thoroughly as in the brain 
due to the technical limitations. In fact, even in patients with myelitis, we 
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detected SC lesions in 78.0%, a finding explained by the limited sensitivity of 
MRI in depicting small and marginally located lesions, and because of 
movement or ghosting artefacts. However, the proportion of SC CIS patients 
with ≥1 SC lesion in our study is very similar to the percentage in a previous 
work.8 Furthermore, presence or number of lesions may not portray the extent 
of the disease properly and other variables such as lesion volume or atrophy 
measures might be necessary, particularly when assessing disability.1, 13, 31-33 
Many of these techniques will aid in our understanding of MS, but it will be 
important to identify which will also be useful for assessing prognosis in the 
clinical practice.           
Therefore, although from the diagnostic point of view the added value of SC 
MRI is moderate in the best-case scenario, SC lesions are independent, highly 
specific predictors of evolution to MS and lesion number is relevant. Importantly, 
SC lesions are an independent risk factor for short-term disability, better 
demonstrated in non-SC CIS in our cohort. Given these results indicate their 
value not only for diagnosis but potentially also for prognosis, further studies 
with larger cohorts and a longer follow-up are justified to help define patient 
groups in which a baseline SC MRI could be more valuable.  
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